文献速递胸部肿瘤消化系统肿瘤骨软组织肉瘤与黑色素瘤

基于分子谱的晚期实体瘤靶向治疗:MyPathway IIa期多篮子研究结果

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.
PubMed 文献 · J Clin Oncol · 2018-01-10

MyPathway是一项多中心、非随机、IIa期多篮子研究,评估四种已获批靶向方案在携带相应分子改变的晚期难治性实体瘤中的疗效与安全性。结论认为这些靶向方案在未获批的难治性实体瘤中单药(不联合化疗)即可产生有意义的缓解。

要点

  • MyPathway评估已获批靶向药在非适应症肿瘤类型中的疗效。
  • HER2扩增/过表达结直肠癌和BRAF V600突变NSCLC显示较高缓解率。

核心结论

  • 四种已获批靶向方案在不联合化疗的情况下,对多种未获批的难治性实体瘤产生有意义的客观缓解。

研究设计与样本

  • 多中心、非随机、IIa期多篮子研究(MyPathway,NCT02091141)。
  • 2014年4月1日至2016年11月1日入组251例35种肿瘤类型的晚期难治性实体瘤患者。
  • 按分子改变分别接受曲妥珠单抗+帕妥珠单抗(HER2)、厄洛替尼(EGFR)、维莫非尼(BRAF)或维莫德吉(Hedgehog通路)治疗。
  • 主要终点为各肿瘤-通路队列内研究者评估的客观缓解率。

主要发现

  • HER2扩增/过表达结直肠癌客观缓解率为38%(14/37;95%CI 23%至55%)。
  • BRAF V600突变非小细胞肺癌客观缓解率为43%(6/14;95%CI 18%至71%)。

临床怎么用

  • 对于携带HER2扩增/过表达、EGFR改变、BRAF V600突变或Hedgehog通路改变的难治性实体瘤,可考虑相应靶向治疗而不联合化疗。
  • HER2扩增/过表达结直肠癌和BRAF V600突变NSCLC是应答较明显的肿瘤-通路组合。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Detection of specific molecular alterations in tumors guides the selection of effective targeted treatment of patients with several types of cancer. These molecular alterations may occur in other tumor types for which the efficacy of targeted therapy remains unclear. The MyPathway study evaluates the efficacy and safety of selected targeted therapies in tumor types that harbor relevant genetic alterations but are outside of current labeling for these treatments. Methods MyPathway ( ClinicalTrials.gov identifier: NCT02091141) is a multicenter, nonrandomized, phase IIa multiple basket study. Patients with advanced refractory solid tumors harboring molecular alterations in human epidermal growth factor receptor-2, epidermal growth factor receptor, v-raf murine sarcoma viral oncogene homolog B1, or the Hedgehog pathway are treated with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. The primary end point is investigator-assessed objective response rate within each tumor-pathway cohort. Results Between April 1, 2014 and November 1, 2016, 251 patients with 35 different tumor types received study treatment. The efficacy population contains 230 treated patients who were evaluated for response or discontinued treatment before evaluation. Fifty-two patients (23%) with 14 different tumor types had objective responses (complete, n = 4; partial, n = 48). Tumor-pathway cohorts with notable objective response rates included human epidermal growth factor receptor-2-amplified/overexpressing colorectal (38% [14 of 37]; 95% CI, 23% to 55%) and v-raf murine sarcoma viral oncogene homolog B1 V600-mutated non-small-cell lung cancer (43% [six of 14]; 95% CI, 18% to 71%). Conclusion The four currently approved targeted therapy regimens in the MyPathway study produced meaningful responses when administered without chemotherapy in several refractory solid tumor types not currently labeled for these agents.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Hainsworth JD, Meric-Bernstam F, Swanton C, et al. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. J Clin Oncol. 2018. PMID: 29320312. doi:10.1200/JCO.2017.75.3780

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。